Statements (49)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:activeDuring |
paliperidone
|
| gptkbp:administrativeDivision |
deep intramuscular injection
|
| gptkbp:brand |
gptkb:Invega_Trinza
|
| gptkbp:clinicalTrials |
Phase III
maintenance treatment recommended for long-term treatment |
| gptkbp:contraindication |
severe renal impairment
hypersensitivity to paliperidone |
| gptkbp:date |
2015-06-17
|
| gptkbp:dosageForm |
suspension
|
| gptkbp:drugInterdiction |
CYP3A4 inducers
CYP2D6 inhibitors |
| gptkbp:endOfLife |
approximately 25 hours
|
| gptkbp:formulation |
long-acting injectable
|
| gptkbp:frequency |
once every three months
|
| gptkbp:hasPopulation |
adults
|
| gptkbp:healthcare |
lifestyle modifications
support resources available importance of regular follow-up recognizing side effects adherence to injection schedule improves adherence to treatment |
| https://www.w3.org/2000/01/rdf-schema#label |
Invega Trinza
|
| gptkbp:inheritsFrom |
4 to 6 weeks
|
| gptkbp:launchSite |
gluteal muscle
|
| gptkbp:manufacturer |
gptkb:Janssen_Pharmaceuticals
|
| gptkbp:marketedAs |
gptkb:Invega_Trinza
|
| gptkbp:nutritionalValue |
liver
|
| gptkbp:patentExpiration |
2026-06-17
|
| gptkbp:relatedTo |
gptkb:Invega
paliperidone palmitate |
| gptkbp:researchInterest |
ongoing studies on efficacy
studies on dosage optimization studies on injection techniques studies on patient satisfaction studies on safety profile |
| gptkbp:route |
intramuscular injection
|
| gptkbp:safetyFeatures |
monitor for metabolic changes
monitor for tardive dyskinesia risk of neuroleptic malignant syndrome |
| gptkbp:sideEffect |
drowsiness
weight gain increased cholesterol hyperglycemia extrapyramidal symptoms |
| gptkbp:storage |
store in a refrigerator
|
| gptkbp:usedFor |
treatment of schizophrenia
|
| gptkbp:waterManagement |
urine
|